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Abstract
Background
The aim of this study was to describe the joint pharmacokinetic-pharmacodynamic model
and evaluate thermal antinociception of a high-concentration formulation of buprenorphine
(Simbadol™) in cats.
Methods
Six healthy cats (4.9 ± 0.7 kg) were included in a prospective, randomized, blinded, cross-
over study. Simbadol™ (1.8 mg mL-1) was administered by the subcutaneous (SC; 0.24 mg
kg-1), intravenous (IV; 0.12 mg kg-1) or buccal (OTM; 0.12 mg kg-1) route of administration
and thermal thresholds (TT) were compared with a saline group (SAL). Thermal threshold
testing and blood sampling were performed at predetermined time points up to 72 hours
including a placebo group. Plasma buprenorphine and norbuprenorphine concentrations
were measured using liquid chromatography mass spectrometry. A bespoke bicompart-
mental pharmacokinetic model simultaneously fitted data from two analytes/three routes of
administration. Temporal changes in TT were analyzed using one-way ANOVA followed by
Dunnett’s test and treatment comparisons using two-way ANOVA with Bonferroni’s correc-
tion (P < 0.05).
Results
Thermal thresholds were significantly increased after SC, IV and OTM from 1–24 hours
(except 2 hours), 0.5–8 hours (except 6 hours), and 1–8 hours (except 6 hours), respectively,
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when compared with baseline. Thermal thresholds were significantly increased after SC (1–
30 hours), IV (1–8 hours) and OTM (1–12 hours) when compared with SAL, but not different
among buprenorphine-treated cats. The absolute buprenorphine clearance was 0.98 L kg-1
hour-1, volume of distribution at steady state was 7.9 L kg-1 and the elimination-half-life was
12.3 hours. Bioavailability for SC and OTM was 94% and 24%, respectively. Subcutaneous
absorption was biphasic. An initial peak (0.08 hours) was followed by a slow (half-life 11.2
hours) and progressive (peak acceleration at 2.8 hours) uptake.
Conclusion
The SC administration of Simbadol™ was characterized by prolonged absorption half-life
and sustained plasma concentrations yielding long-lasting antinociception ( 24 hours)
when compared with the IV and OTM routes.
Introduction
Buprenorphine is an opioid analgesic drug that is commonly administered for the treatment
of feline perioperative pain. The use of buprenorphine in this species has been recently
reviewed in both experimental and clinical setting [1]. At standard clinical doses (0.02 mg
kg-1) and concentrations (0.3 mg mL-1), buprenorphine is poorly absorbed and has limited
antinociceptive effect after subcutaneous (SC) administration [2]. Further investigation
showed that increased doses (> 1.2 mg kg-1) administered by this route of administration can
provide prolonged antinociception and improved absorption compared with standard doses
[3]. Simbadol™ (1.8 mg mL-1, buprenorphine hydrochloride; Zoetis, NJ, USA) is an FDA-
approved high-concentration formulation of buprenorphine for cats. The drug is indicated for
the control of postoperative pain and approved for subcutaneous only administration at 0.24
mg kg-1 every 24 hours up to three days. There is an interest in investigating the antinocicep-
tive effects, pharmacokinetics (PK) and pharmacodynamics (PD) of this high-concentration of
buprenorphine after SC, buccal or intravenous (IV) administration in conscious cats. Using a
joint PK model of the three routes of administration would provide more robust estimates of
the PK parameters of Simbadol™ when compared with traditional PK methods analyzing each
route of administration separately [4].
The aims of this study were to 1) describe a joint PK modelling of Simbadol™ in awake cats,
2) evaluate the time-course of thermal antinociception in the same individuals, and 3) estimate
PD parameters by PK-PD modeling. It was hypothesized that 1) joint PK would provide a
robust method for understanding PK modeling, 2) Simbadol™ would produce dose-dependent
thermal antinociception and 3) PK-PD modeling would explain how plasma concentrations of
buprenorphine and thermal antinociception are correlated after administration of Simbadol™.
This study reports joint PK modelling and PK-PD modelling of buprenorphine after the
administration of Simbadol™.
Materials and methods
Animals
The animal care committee of the Universite´ de Montre´al approved the study protocol
(14-Rech-1761). This study is reported according to the ARRIVE guidelines [5].
PK-PD of a high-concentration formulation of buprenorphine in cats
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Six healthy adult domestic short haired cats (4.9 ± 0.7 kg, four males and two females)
were included in the study. Cats were purchased from another research laboratory which
they had been used as controls for another study. They were all adopted at the end of the
study. The cats were group housed in a long-term accommodation (room) with temperature
(20–22˚C) and humidity (40–70%) control, and according to the Canadian Council for Ani-
mal Care guidelines.
The cats were fed a commercially available diet twice daily with ad libitum water. All cats
were healthy based on physical examination, hematology and serum chemistry profile. Envi-
ronmental enrichment was provided following the American Association of Feline Practition-
ers and International Society of Feline Medicine guidelines [6]. During testing, cats were
housed individually in stainless steel adjacent cages (67 x 55 x 68 cm3). Body weight was moni-
tored on a weekly basis. Cats were acclimated to the testing procedures several weeks before
the study began (S1 File—Appendix 1).
Experimental design
The experimental phase was divided into two parts.
Phase I (Thermal thresholds after saline 0.9%)—Cats were administered sterile saline 0.9%
(NaCl 0.9%; Baxter, ON, Canada) by the subcutaneous route of administration (same volume
as 0.24 mg kg-1 dose of Simbadol™) between the shoulder blades, and thermal thresholds (TT)
were evaluated for up to 72 hours (see time points below). Blood collection or venous catheter-
ization was not performed on Phase I to avoid unnecessary stress to the cats.
Phase II (Cross-over thermal threshold testing and blood sampling)—Phase II used a ran-
domized, prospective, blinded, crossover study design with a 14-day minimum wash-out
period between treatments. Approximately 12 hours before TT testing, a short-term catheter
was introduced in the cephalic vein and general anesthesia was induced and maintained using
8 mg/kg of propofol (Diprivan; AstraZeneca, ON, Canada) and isoflurane (Isoflurane, Aer-
rane; Baxter, ON, Canada) in 100% oxygen, respectively. A central venous catheter (Peel Away
Single Lumen 19Ga, PI-1910; Mila International, KY, USA) was aseptically introduced in the
jugular vein, sutured, and covered with light soft bandage. The jugular catheter was used for
blood sampling throughout the study and removed after the testing period. The cephalic cathe-
ter was maintained in all cats until treatment administration and was used for administration
of the test drug by the IV route when applicable. It was removed immediately after treatment
administration. At the end of the procedure, cats were allowed to recover from anesthesia in a
calm and quiet environment.
Cats were randomly assigned to receive one of the following treatments: a. Simbadol™ by
the intravenous route (IV, 0.12 mg kg-1) via cephalic catheter followed by flush with saline; b.
Simbadol™ by the subcutaneous route (SC, 0.24 mg kg-1). The drug was injected between the
shoulder blades; and c. Simbadol™ by the buccal route (OTM, 0.12 mg kg-1). The volume of
buprenorphine was slowly administered into the cheek pouch using a 1mL syringe in the con-
tralateral side to the central venous catheter position. Doses for the IV and OTM routes were
based on previous safety and efficacy studies performed by the manufacturer, and clinical
interest. Randomization was performed using an online software (www.randomization.com).
Randomization and treatment administration were performed by two individuals who were
not involved with TT testing (PS/GD).
Measurements of thermal threshold
Antinociception was evaluated using a wireless TT device (WTT1, Topcat Metrology Ltd,
UK). The test has been validated in free-ranging cats [7] and several studies using the TT
PK-PD of a high-concentration formulation of buprenorphine in cats
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device and evaluating the antinociceptive effects of buprenorphine have been reported in the
species [3, 8–16]. The equipment was calibrated and maintained according to the manufactur-
er’s recommendations. The TT device is incorporated into an elasticated vest, containing a
wireless receiver, power supply, LCD display and thermal probe which is applied around the
thorax of a free roaming cat. An adjustable air bladder is used to maintain consistent pressure
and direct contact of the temperature probe with the shaved lateral thorax. For each measure-
ment, the skin temperature (ST) is recorded prior to thermal stimulus. For TT testing, the
evaluator triggers a ramped heat stimulus (0.6˚C second−1) using a hand-held device which is
stopped once the cat exhibits a behavioral response (e.g. vocalization, rolling, jumping, etc.;
considered the TT), or when the cut-off of 55˚C is reached. If cut-off was reached, this value
(55˚C) was used as the TT. A single evaluator (BM) performed TT testing and was blinded to
the treatments. Thermal threshold testing was evaluated before (baseline; time 0) and at 0.5, 1,
2, 4, 6, 8, 12, 24, 30, 36, 48, 60 and 72 hours after treatment administration for both phases. At
each testing day and 30 minutes after placement of TT device, baseline values were determined
using the mean of three recordings performed at 15-minute intervals prior to treatment.
Any behavioral changes, adverse reactions or additional observations were recorded during
the testing period. Oral pH was measured at baseline (pre-treatment) and at 48 hours after
treatment.
Blood sampling
During Phase II, blood sampling was performed from the jugular vein via central venous cath-
eter after 2 and 8 min of treatment administration, and after each TT testing. The volume of
blood collected was adjusted for each individual so that less than 10% of the cat’s total blood
volume was removed over the study period (2 mL maximum per sample). After each collec-
tion, the catheter was flushed with 1 mL of heparinized saline and the injection plug was
changed to minimize contamination of subsequent sampling. Blood was transferred to
K3EDTA tubes and centrifuged at 2000 g for 10 minutes. Plasma was separated and stored at
-80˚C before buprenorphine/norbuprenorphine HPLC-MS/MS analysis.
Buprenorphine and norbuprenorphine assay
Appendix 2 (S2 File) provides description of the analytical method for buprenorphine and
norbuprenorphine using high performance liquid chromatography-mass spectrometry
(HPLC-MS/MS). The method met standards for sensitivity, linearity, precision, accuracy and
stability generally accepted in bioanalytical chemistry [17]. Limits of quantification were 0.1 to
100 ng mL-1 for buprenorphine and 0.2 to 100 ng mL-1 for norbuprenorphine.
Joint PK and PK-PD modeling
Population pharmacokinetic modelling was performed with Phoenix NMLE1, version 1.3,
Certara (Princeton, NJ, USA) installed on a Dell Precision 7510 computer (core i7). Full
description of the joint population PK and PK-PD model is provided in Appendix 3 (S3 File).
Briefly, a two compartmental model was used to simultaneously model the plasma concentra-
tion-time curves of buprenorphine and norbuprenorphine (formed through conversion
from buprenorphine and first pass effect). The SC, IV and OTM administration routes were
included jointly in the PK model to increase the number of degree of freedom. In order to
explore the biphasic nature of the SC absorption, several complex candidate models were elab-
orated and compared. Estimates of PK variables were provided with inter-individual variability
(IIV%). Population PD parameters were estimated by sequential population PK-PD modeling.
PK-PD of a high-concentration formulation of buprenorphine in cats
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The best PD model was selected among a series of candidate models including negative hyster-
esis and antinociceptive effects of buprenorphine with or without norbuprenorphine.
Statistical analysis
Prospective power analysis concluded that a sample size of six cats would be sufficient to detect
mean temperature differences of> 3.2˚C with a power of 0.8 and an alpha level set at 0.05
based on a previous study [18]. Statistical analyses were performed using a software (GraphPad
Prism, GraphPad software Inc., California, USA). Thermal threshold values were used as the
outcome variable for comparisons. Thermal thresholds for each treatment were analyzed for
temporal changes using one-way ANOVA for repeated measures followed by the Dunnett’s
test when appropriate. Treatment comparisons were made using two-way ANOVA followed
by Bonferroni’s correction (p< 0.05). Data were expressed as mean ± SD.
Results
Adverse effects and behavioral changes—Adverse effects were not observed in Phase I. Overall,
signs of euphoria (rolling, kneading with thoracic paws, meowing, and purring) and agitation
were recorded after treatment with all routes/cats in Phase II. Vomiting and diarrhea were
observed in two cats during the study; one in the IV group (diarrhea on day 2 and vomiting
once on day 3) and one in the OTM group (diarrhea only on day 3). Both cats remained bright
and alert and their clinical signs spontaneously resolved. Short-term hypersalivation was noted
in two cats immediately following OTM treatment. Dysphoria was not observed in this study.
Mean ± SD of oral pH before and after (48 hours) all treatments were 8.8 ± 0.4 and 8.7 ± 0.5,
respectively.
Skin temperature and thermal thresholds—Mean ± SD baseline ST for all treatments
(Phase I and II) was 36.9 ± 0.6˚C. Skin temperature (ST) was not significantly increased after
IV, OTM or saline 0.9% treatments when compared with baseline. Skin temperature was sig-
nificantly increased in SC treatment between 60 and 720 minutes (except 120 and 360 minutes;
p = 0.0001). These values were within normal range and hyperthermia (ST > 39.5˚C) was not
observed. Skin temperature was significantly increased from 0 to 3600 minutes (except 1440 to
2160 minutes) after IV treatment, from 0 to 4320 minutes (except 30 and 1800 to 3600 min-
utes) after SC treatment, and from 0 to 4320 minutes (except 720 to 2160 minutes) after OTM
treatment (p< 0.05) when compared with saline 0.9% (Table 1).
Mean ± SD baseline TT for all treatments (Phase I and II) was 45.3 ± 1.7˚C. Thermal
thresholds were not significantly different among IV, SC and OTM treatments. Thermal
thresholds were significantly increased after IV treatment between 30 and 480 minutes (except
360 minutes; p< 0.001), after SC treatment between 60 and 1440 minutes (except 120 minutes;
p< 0.001), and after OTM treatment between 60 and 480 minutes (except 360 minutes;
p< 0.001) when compared with baseline values. Thermal thresholds were significantly
increased after IV treatment from 30 to 480 minutes, after SC treatment from 60 to 1800 min-
utes, and after OTM from 60 to 720 minutes when compared with saline 0.9% (p< 0.05).
Thermal thresholds did not increase after treatment with saline 0.9% (Table 2).
Blood sampling—A central jugular catheter was removed by one cat at 24 hours after IV
administration of Simbadol™. Fig 1 shows mean plasma concentration profiles for buprenor-
phine and norbuprenorphine (Fig 1)
Pharmacokinetic modeling and parameters—Fig 2 shows the structure of the final popula-
tion PK model for buprenorphine and norbuprenorphine (Fig 2). For all parameters listed
below, the inter-individual variability (IIV %) is reported immediately following each estimate
where appropriate.
PK-PD of a high-concentration formulation of buprenorphine in cats
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Fig 1. Mean plasma concentrations of buprenorphine and norbuprenorphine (± SD) in six conscious cats. IV
(0.12 mg/kg buprenorphine IV, red triangles); SC (0.24 mg/kg buprenorphine SC, blue diamonds); OTM (0.12 mg/kg
buprenorphine buccal route of administration, green squares); [Plasma] (Plasma concentration).
https://doi.org/10.1371/journal.pone.0176443.g001
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For buprenorphine, a model that best predicted the individual observed plasma concentra-
tions after SC route (see S3 File—Appendix 3), and that has been previously used for systemic
absorption of local anesthetic after perineural administration (16), was used. This model com-
bined Inverse Gaussian (IG, rapid but short duration) and Time-dependent (TD, delayed and
progressive onset) inputs. The three routes of administration shared four central PK parame-
ters; clearance (CL = 0.98 L kg-1 hour-1, 2.4%), volume of distribution of the central compart-
ment (V1 = 0.75 L kg-1, 11.3%), intercompartmental clearance (CL2 = 0.70 L kg-1 hour-1, 0%)
and peripheral volume of distribution (V2 = 7.15 L kg-1, 8.1%) with a common proportional
residual error term. The total body clearance of buprenorphine was moderate to high
Fig 2. Pharmacokinetic-pharmacodynamic (PK-PD) model representation for buprenorphine and norbuprenorphine after subcutaneous,
intravenous and buccal administration in six cats. For the SC route, combined Inverse Gaussian (IG, rapid but short lasting) and Time-dependent
(TD, delayed and progressive onset) inputs. Buprenorphine central PK parameters; clearance (CL), volume of distribution of the central compartment
(V1), intercompartmental clearance (CL2), volume of distribution of peripheral compartment (V2). Norbuprenorphine central PK parameters: clearance
(CLMet), volume of distribution of the central compartment (V1Met), intercompartmental clearance (CL2Met) and volume of distribution of the
peripheral compartment (V2 Met). Rate constant of transformation from parent to metabolite (KaMet), first pass norbuprenorphine absorption rate
(Kafirst-pass). PK parameters specific to OTM route: bioavailability (FOTM, parent and metabolite), absorption rate constant (kaOTM). PK parameters
specific to SC route: bioavailability (FSC), proportion taken by IG input (BIO) and time-dependent delayed input (1-BIO), mean input rate time (MAT)
was 7.21 h (3.5%) and variance of the input time (CV), maximal absorption rate constant (kaSC), time to achieve 50% of this maximum rate (T50).
https://doi.org/10.1371/journal.pone.0176443.g002
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according to Toutain et al. 2004 [19]. Volume of distribution at steady-state (Vdss) was 7.89 L
kg-1. The average beta elimination half-life for this bicompartmental model was 12.3 hours
[20].
For PK parameters, specific to the OTM treatment, the bioavailability FOTM was 23.6%
(IIV 25%) and the absorption rate constant (kaOTM) was 1.67 hour
-1 (25.1%), yielding an
absorption half-life of 0.42 hours. For the SC treatment, the total bioavailability FSC was 94%
(IIV 23.4%). A proportion of 10.1% (IIV 113%) of FSC was absorbed through early uptake
(BIO = proportion taken by IG input) and the rest (1-BIO = 89.1%) was absorbed through a
time-dependent delayed input (TD). For the IG input of the SC absorption, mean input rate
time (MAT) was 7.21 hours (3.5%) and variance of the input time (CV) was 5.46 (0.5%). This
translated into an initial peak of plasma concentration observed at 0.08 hours (5 minutes, at
Tmax, the mode of the IG function) corresponding to 10% of the buprenorphine being rapidly
absorbed. For the TD input, the maximal absorption rate constant (kaSC) was 0.062 hour
-1
(14.9%), yielding a slow late absorption half-life (11.2 hours). The time to achieve 50% of this
maximum rate (T50) was 2.8 hour (27%).
For norbuprenorphine, it was thought that it was exclusively generated from plasma bupre-
norphine degradation, with KaMet the irreversible conversion rate constant from the parent
drug to its metabolite. The PK of norbuprenorphine was best described using a two compart-
ment model for which four parameters common to the three administration routes could
be estimated: norbuprenorphine clearance (CLMet = 0.42 L kg
-1 hour-1, IIV 4.3%), volume of
distribution of the central compartment (V1Met = 0.323 L kg
-1, 0.1%), intercompartmental
clearance (CL2 Met = 7.662 L kg
-1 hour-1) and volume of distribution of the peripheral com-
partment (and V2 Met = 4.69 L kg
-1). Random effects for CL2 Met and V2 Met were not esti-
mated. In a second step, a first pass effect was included in the model to account for the higher
norbuprenorphine exposure after OTM administration when compared with other routes (Fig
2). The rate constant of transformation from parent to metabolite was estimated using the IV
and SC datasets (KaMet = 0.196 hour
-1, 19%) yielding a transformation half-life 3.5 hours. The
KaMet was then fixed to allow estimation of the first pass norbuprenorphine absorption rate
constant using full 3-routes dataset (Kafirst-pass 0.626 hour
-1, 6.9%, absorption half-life 1.1
hours) and FOTM (parent and metabolite OTM bioavailability). The amount absorbed as nor-
buprenorphine via first pass after OTM administration contributed to approximately 1% out
of the value of FOTM (23.6%).
PK-PD modeling—Several models were evaluated (S3 File—Appendix 3) and the best
one was selected based on the Bayesian Information Criterion value and the identifiability of
parameters. The model could reliably estimate the effect of buprenorphine but not that of
norbuprenorphine. A hypothetical effect-compartment accounted for the delay in attaining
maximal effect in relation to drug concentrations in the central compartment [21]. The link
between effect site buprenorphine concentration (Ce) and thermal antinociceptive effect (E)
was modelled with an Emax function according to equation 1:
Antinociceptive effect ðEÞ ¼ T0 þ
Emax  C ne
EC n
50
þ C ne
where T0 is the estimated baseline thermal threshold (˚C), Emax is the estimated maximal effect
(˚C), EC50 is the plasma concentration achieving 50% of Emax and n is the slope parameter of
the concentration effect curve. The transfer rate constant Ke0 was 0.52 hour-1 (IIV 0%). The
estimated maximal effect Emax was 5.62˚C (IIV 0%) over the baseline thermal threshold T0 =
46.1 (IIV 0%). Buprenorphine EC50 (potency) was 2.13 ng mL
-1 (IIV 447%) with a slope (n) of
1.54 (91%).
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Discussion
Subcutaneous administration of the drug provided long-lasting thermal antinociception ( 24
hours). These effects were prolonged compared with the IV (8 hours) and OTM ( 8 hours)
treatments. The combined modelling approach provided a robust model to capture the com-
plex absorption of the SC treatment. Despite limitations in the thermal antinociceptive model
such as right censored data (due to the safety cut-off) and individual variability, the final
PK-PD model could describe and predict the prolonged analgesic effects of Simbadol™ after
SC administration due to is biphasic rapid and slow absorption kinetics.
The duration of thermal antinociception was consistently longer in this study compared
with traditional doses of buprenorphine, regardless of route of administration. In previous
studies that tested thermal antinociception of buprenorphine in cats, antinociception was
reported between 4 and 12 hours following 0.01 mg kg-1 IM buprenorphine [8]. Further inves-
tigation, including IV and OTM administration at doses of 0.01–0.02 mg kg-1 found shorter
durations of antinociception (between 0.5 to 6 hours) [9, 12–14, 18, 22]. Additionally, it
appeared that low dose buprenorphine administered SC was ineffective, with near undetect-
able plasma concentrations that did not provide thermal antinociception [18]. Clinical guide-
lines would not recommend the SC route of administration for the management of pain using
low doses of buprenorphine [1]. In the current study, the increased dose of buprenorphine
prolonged the duration of antinociceptive effect in all three routes of administration, however
it is clear that the SC route of administration provided superior duration when compared with
all others. A recent study compared thermal antinociceptive effects of buprenorphine using
different doses (0.02–0.24 mg kg-1) and found thermal antinociception of up to 30 hours when
0.12 mg kg-1 or more was administered [3]. In the study herein, the SC administration pro-
duced consistent elevations in TT when compared with either baseline or placebo treatments.
Joint modeling provided robust estimates of the pharmacokinetic parameters of Simbadol™
for several reasons. Traditional methods used for pharmacokinetic modeling of buprenor-
phine in cats have studied each route of administration separately [9, 16, 18], instead of pool-
ing data from crossover studies to strengthen estimation of parameters shared across routes of
administration (CL, V1, CL2, V2). In the present study, six individuals were used in a typical
cross-over design, yielding 18 related (six cats, three routes of administration) plasma concen-
tration-time curves. Amalgamation of rich PK data from different routes in the same model
using non-linear mixed effect modelling is encouraged to optimize data, and increase statisti-
cal power to address complex absorption or disposition kinetics [4]. In the present study, the
slow SC absorption kinetic could be unraveled due to the inclusion of IV data in the model
(during exploratory deconvolution exercise or in the final model), which is a crucial require-
ment to study atypical drug absorption profiles [23]. The slow SC absorption resulted in a
delayed Tmax compared with the OTM route. However, the beta elimination half-life of 12.3
hours was still longer than the half-life of the slowest SC absorption input (11.2 hours for TD
input), therefore ruling out a flip-flop phenomenon.
The kinetic of norbuprenorphine followed closely the kinetic of the parent drug. Not only
peak norbuprenorphine concentrations appeared much earlier after IV or OTM when com-
pared with SC administration, but the plasma norbuprenorphine concentration-time curve
also displayed double peaks corresponding to the one observed for buprenorphine. Hence,
joint modelling of buprenorphine-norbuprenorphine further corroborated the slow biphasic
SC buprenorphine uptake using a robust model.
The biphasic input model used has been reported in a previous study where a double peak
phenomenon in the plasma concentration-time curve of ropivacaine after femoral blockade
was observed in people [24]. After a rapid short-lasting absorption from the perineural space,
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the secondary slower input was accounted by either (i) partitioning of the drug in the sur-
rounding tissues and subsequent mobilization with exercise-induced increase in perfusion or
(ii) initial precipitation in surrounding tissues due to a low aqueous solubility and gradual re-
dissolution, creating a concentration gradient that promotes systemic absorption (16). It is
possible that a similar process occurs in the cat following SC administration of Simbadol™.
The pharmacokinetic parameters estimated in the current study are similar to those
reported in the literature (Table 3) using buprenorphine in cats [9, 16, 18, 25]. Some variability
exists due to different bioavailability particularly in routes other than IV. For example, the
elimination t1/2 was longer in the current study, yet the clearance and VDSS are similar across
studies. One potential limitation in the present study is the variable doses between OTM/IV
and SC (0.12 mg kg-1 vs 0.24 mg kg-1). In a study from Taylor et al, increasing dosages of
buprenorphine (0.02 to 0.24 mg kg-1 SC) revealed saturation kinetics (Table 4) (3). Similar
clearances were observed, however the lack of IV administration in the latter study does not
allow for an estimate of bioavailability, making VDSS comparisons difficult. Indeed, the elimi-
nation half-life was shorter in the current study when compared with Taylor et al. This is likely
a result of the variable formulations used in that study, which might alter drug absorption.
Current literature on OTM or sublingual administration of buprenorphine has suggested
that jugular sampling may be inappropriate for PK studies using this drug because it overesti-
mates bioavailability due to sampling a vessel which drains the site of administration [26].
There are two studies in particular in which this overestimation has been documented. One
Table 3. Median pharmacokinetic estimates according to different dosage regimens and studies.
Parameter Units Current
Study
Hedges
et al. 2014
Steagall et al.
2013
Robertson et al.
2003
Taylor
et al.
2001
Dose μg kg-1 120–240 20 10
Route All routes IV OTM IV IM SC OTM IV IM
Clearance or
CL/F
L kg-1
hour-1
0.98 1.4 3.8* 0.5 0.8* - 0.51* 1 1.4*
VD-Steady State L kg-1 7.9 11.6 25.9 2.9 10.3 - 3.4 7.1 8.9
Elimination half-
life
Hour 12.3 9.8 8.9 7 7.7 - 5.8 6.9 6.3
Values converted from published estimates to standardize units. Intravenous (IV), Buccal (B), Intramuscular
(IM), Subcutaneous (SC).
*Variable bioavailability F%.
https://doi.org/10.1371/journal.pone.0176443.t003
Table 4. Median pharmacokinetic estimates using high doses of buprenorphine by different routes of
administration in cats.
Parameter Units Current Study Taylor et al. 2015
Dose μg kg-1 120–240 20 60 120 240
Route All routes SC SC SC SC
Clearance or CL/F L kg-1 hour-1 0.98 - 1.0 0.92 0.94
VD-Steady State L kg-1 7.9 - 0.58* 0.59* 0.66*
Elimination Half-life Hour 12.3 2.7 22.4 19.7 17.2
Values converted from published estimates to standardize units, Subcutaneous (SC),
*Vdbeta/F (L/mL)
https://doi.org/10.1371/journal.pone.0176443.t004
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study found an F of 116% and the other 139% in cats [9] and horses [27], respectively. When
carotid arterial, jugular venous and saphenous sampling sites were simultaneously compared
in cats, F was reported as 32%, 47% and 23% respectively [26]. These factors were considered
in the design of the current study. However, placing a catheter in the carotid artery three times
during the study and for prolonged periods was found to be risky with a potential for blood
sampling failure. The authors chose to place a central venous catheter to collect samples from a
central site, rather than peripheral venous site. A pilot study showed that placing these cathe-
ters via the jugular site (versus medial saphenous) was both easy and repeatable, and the
sampling port would require minimal restraint of the cats. As a further step to minimize over-
estimation, cats receiving OTM treatment would have the dose administered in the contralat-
eral cheek relative to the jugular catheter. The reported bioavailability of the OTM treatment
in the current study (F = 23.6%) is closer to that of the peripheral venous sample obtained in
the previous study [26].
The SC route of administration provided prolonged analgesia due to its sustained plasma
concentrations and the relationship between plasma, effect-side concentrations and time
course of antinociception predicted by the sequential population PK/PD model. Despite con-
sistent thermal antinociception based on averaged group data, the fit of the pharmacodynamic
model was less satisfactory on an individual basis. Great individual variability in response to
thermal stimulation was observed, however, similar findings have been reported (16). Treat-
ments produced significant and variable behavioral and TT changes that could have affected
the quality of the PK/PD model fit.
Other limitations in the present study were the inclusion of a safety threshold that produces
artificially truncated data. A log likelihood approach to model right censored data as proposed
by Sadiq et al. [28] was attempted but did not allow successful modelling with Phoenix NLME.
In addition, PD modelling has not been described for norbuprenorphine in cats. In other spe-
cies, the norbuprenorphine is between 50 and 200-fold less potent than buprenorphine with
regards to its respiratory depressant or antinociceptive effects [29]. Multiple models including
both drug and metabolite were attempted to evaluate the contribution of norbuprenorphine to
thermal antinociception (S3 File—Appendix 3), however the PD parameters for norbuprenor-
phine were not identified.
Conclusion
Subcutaneous administration of Simbadol™ (Buprenorphine HCl, 1.8 mg ml-1) provided long-
lasting thermal antinociception ( 24 hours) in conscious cats. These effects are prolonged
compared with the IV (8 hours) and OTM ( 8 hours) treatments. Joint pharmacokinetic-
pharmacodynamic modelling showed prolonged plasma concentrations for the SC route.
Despite the difficulties with pharmacodynamic modelling, the final model strongly supported
the long acting analgesia provided by the drug. Advanced mathematical modelling of pooled
data from different routes or parent-metabolite drug combinations and different studies allows
leveraging of information to improve the understanding of complex pharmacokinetics.
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